Cystic Fibrosis Foundation invests $13m in SpliSense
The investment comes following positive results in an initial efficacy trial, Phase IIa, in which an improvement in lung function was demonstrated in some 70% of patients
Assessment
A specialized health foundation is directing significant funds into SpliSense after early clinical data showed lung function improvement in most participants. The investment signals confidence in the drug's mechanism, though Phase IIa results are still preliminary. The next milestone will be whether larger trials replicate these outcomes.